About the Company
equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EQ News
Buy Rating Affirmed for Equillium Amid Promising Clinical Trials and Potential Financial Upsides
In a report released on March 25, Thomas Smith from Leerink Partners reiterated a Buy rating on Equillium (EQ – Research Report), with a ...
Equillium gets grant for inhibitors of cytokine activity using peptide antagonists
Discover Equillium Inc's groundbreaking patent on peptide antagonists targeting ?c-family cytokines linked to leukemia and autoimmune disorders. This innovative patent offers therapeutic, cosmetic, ...
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
Equillium, Inc. (EQ) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.08 per share a year ago. These figures ...
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory ...
Individual investors account for 41% of Equillium, Inc.'s (NASDAQ:EQ) ownership, while insiders account for 20%
Key Insights The considerable ownership by individual investors in Equillium indicates that they collectively have ...
Equillium, Inc. (EQ) Interactive Stock Chart - Yahoo Finance
LA JOLLA, Calif., March 22, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory ...
Equillium: Q4 Earnings Insights
Equillium EQ reported its Q4 earnings results on Monday, March 25, 2024 at 04:01 PM. Here's what investors need to know about the announcement. Equillium beat estimated earnings by 59.0%, reporting an ...
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Equillium, Inc. (0FY.F)
Simply Wall St. Even after rising 85% this past week, Equillium (NASDAQ:EQ) shareholders are still down 85% over the past three years It is doubtless a positive to see that the Equillium, Inc. ( ...
Equillium, Inc. (0A4D.L)
Simply Wall St. Even after rising 85% this past week, Equillium (NASDAQ:EQ) shareholders are still down 85% over the past three years It is doubtless a positive to see that the Equillium, Inc. ( ...
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...
Loading the latest forecasts...